Govardhanan Nagaiah, MD
Hematology & Oncology · Goodyear, AZNPI 1386736585
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 17.1%. Reporting peaked in 2019 at $66,782 and has fallen 93.0% since, to $4,700 in 2025. Among hematology & oncology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,293 payments — averaging $171.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$38K
- Sobi, Inc$35K
- Regeneron Healthcare Solutions, Inc.$32K
- Dova Pharmaceuticals$23K
- Pfizer$10K
- Amgen$9K
- plus $73K from 54 others
Across 379 payments — averaging $3552.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$260K
- E.r. Squibb & Sons, L.L.C.$238K
- Genentech, Inc.$217K
- Eli Lilly$173K
- Janssen Research & Development, LLC$159K
- Acerta Pharma LLC$136K
- plus $162K from 9 others
What the payments were for
- Consulting fees$48,28322%
- Speaking & faculty fees$132,80160%
- Travel & lodging$12,3806%
- Food & beverage$27,77913%
- Education$5390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$221,780 in reported general payments places this provider in the 95th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 66 | $982,907 |
| JakafiRuxolitinib Phosphate | 44 | $799,639 |
| BrukinsaZanubrutinib | 55 | $773,596 |
| VerzenioAbemaciclib | 33 | $540,786 |
| Lenalidomide | 21 | $335,572 |
| PomalystPomalidomide | 12 | $329,706 |
| ImbruvicaIbrutinib | 22 | $328,084 |
| ErleadaApalutamide | 22 | $320,636 |
| RevlimidLenalidomide | 16 | $285,343 |
| VonjoPacritinib Citrate | 11 | $262,959 |
| DopteletAvatrombopag Maleate | 13 | $260,213 |
| XtandiEnzalutamide | 18 | $249,756 |
| TagrissoOsimertinib Mesylate | 12 | $198,081 |
| VenclextaVenetoclax | 16 | $166,933 |
| EliquisApixaban | 152 | $144,786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $8,262 | $1,180,98878 claims |
| Incyte CorporationJakafi | $4,810 | $799,63944 claims |
| Beigene USA, Inc.Brukinsa | $4,602 | $773,59655 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $685 | $541,63587 claims |
| Johnson & JohnsonErleada, Xarelto | $1,904 | $449,260150 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $6,098 | $329,70612 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $220 | $328,08422 claims |
| Bristol Myers SquibbRevlimid | $3,559 | $285,34316 claims |
| Dova PharmaceuticalsDoptelet | $22,704 | $260,21313 claims |
| Astellas Pharma US IncXtandi | $269 | $249,75618 claims |
| AbbVieVenclexta | $4,216 | $166,93316 claims |
| PfizerEliquis | $10,320 | $144,786152 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Goodyear
- Jeremy LarsenGoodyear$117K
- Sujith KalmadiChandler$1.4M
- Jeffrey SchriberScottsdale$715K
- Javier MunozPhoenix$638K
- Tanios Bekaii-SaabScottsdale$527K
- Rajesh KukunoorScottsdale$499K
- Sumit MadanGilbert$422K
- Christopher ChenTucson$370K
- Rachna ShroffTucson$250K
- Yousef ZakhariaScottsdale$214K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.